Russell Investments Group
TBPH

Russell Investments Group’s Theravance Biopharma TBPH Stock Holding History

Russell Investments Group’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$412K Buy
24,193
+20,319
+524% +$336K ﹤0.01% 2872
2026
Q1 		$62.9K Sell
3,874
-174
-4% -$3.08K ﹤0.01% 3241
2025
Q4 		$75.7K Sell
4,048
-1,014
-20% -$16.8K ﹤0.01% 3154
2025
Q3 		$73.9K Sell
5,062
-37,429
-88% -$473K ﹤0.01% 3133
2025
Q2 		$469K Sell
42,491
-5,568
-12% -$54.1K ﹤0.01% 2360
2025
Q1 		$429K Buy
48,059
+26,069
+119% +$243K ﹤0.01% 2346
2024
Q4 		$207K Sell
21,990
-25,108
-53% -$228K ﹤0.01% 2533
2024
Q3 		$380K Sell
47,098
-3,420
-7% -$29.6K ﹤0.01% 2352
2024
Q2 		$428K Buy
50,518
+5,404
+12% +$48.8K ﹤0.01% 2254
2024
Q1 		$405K Buy
45,114
+16,135
+56% +$150K ﹤0.01% 2267
2023
Q4 		$326K Sell
28,979
-17,524
-38% -$176K ﹤0.01% 2328
2023
Q3 		$401K Sell
46,503
-7,115
-13% -$68.7K ﹤0.01% 2301
2023
Q2 		$555K Sell
53,618
-19,236
-26% -$212K ﹤0.01% 2192
2023
Q1 		$790K Buy
72,854
+83
+0.1% +$878 ﹤0.01% 2082
2022
Q4 		$816K Buy
72,771
+13,801
+23% +$145K ﹤0.01% 2073
2022
Q3 		$596K Sell
58,970
-7,191
-11% -$67.4K ﹤0.01% 2173
2022
Q2 		$598K Sell
66,161
-5,084
-7% -$46.8K ﹤0.01% 2197
2022
Q1 		$680K Sell
71,245
-40,955
-37% -$401K ﹤0.01% 2130
2021
Q4 		$1.24M Buy
112,200
+44,220
+65% +$385K ﹤0.01% 2044
2021
Q3 		$501K Sell
67,980
-14,014
-17% -$157K ﹤0.01% 2458
2021
Q2 		$1.19M Sell
81,994
-5,128
-6% -$96.3K ﹤0.01% 2230
2021
Q1 		$1.78M Sell
87,122
-16,106
-16% -$306K ﹤0.01% 1938
2020
Q4 		$1.83M Sell
103,228
-9,937
-9% -$178K ﹤0.01% 1803
2020
Q3 		$1.67M Buy
113,165
+16,993
+18% +$318K ﹤0.01% 1800
2020
Q2 		$2.02M Buy
96,172
+13,804
+17% +$355K ﹤0.01% 1629
2020
Q1 		$1.9M Buy
82,368
+72,968
+776% +$1.83M ﹤0.01% 1493
2019
Q4 		$243K Buy
+9,400
New +$183K ﹤0.01% 2642
2017
Q4 		– Sell
-18,508
Closed -$634K – 3007
2017
Q3 		$634K Sell
18,508
-2,957
-14% -$96.7K ﹤0.01% 2352
2017
Q2 		$855K Buy
21,465
+6,777
+46% +$261K ﹤0.01% 2191
2017
Q1 		$541K Hold
14,688
– – ﹤0.01% 2392
2016
Q4 		$464K Buy
+14,688
New +$456K ﹤0.01% 2491

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Russell Investments Group's TBPH Position: Q2 2026 in Review

Russell Investments Group increased its Theravance Biopharma (TBPH) stake by 524% in Q2 2026, buying an estimated $336K and bringing the position to 24,193 shares worth $412K. The position accounts for ﹤0.01% of the portfolio, ranked #2872.

Russell Investments Group first reported a position in TBPH in Q4 2016 and has held it in 31 quarters since. The position peaked at $2.02M in Q2 2020. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Russell Investments Group held 24,193 shares of Theravance Biopharma worth $412K as of Q2 2026.
  • Russell Investments Group bought 20,319 Theravance Biopharma shares in Q2 2026, an estimated $336K.
  • Theravance Biopharma made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #2872 holding.
  • Russell Investments Group first reported a position in Theravance Biopharma in Q4 2016 and has held it in 31 quarters since.
  • Russell Investments Group's Theravance Biopharma position peaked at $2.02M in Q2 2020.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.